Measurement of circulating levels of VEGF-A, -C, and -D and their receptors, VEGFR-1 and -2 in gastric adenocarcinoma

Table 2 Associations between serum concentrations (pg/mL) of VEGF-A, -C, and -D, and VEGFR-1 and -2 and clinco-pathological features in 76 patients of gastric adenocarcinoma and 76 control subjects (mean ± SD )

Pathological	n	VEGF-A	VEGF-C	VEGF-D	VEGFR-1	VEGFR-2
Site
Distal	43	522.9 ± 371.6	6035.5 ± 2544.3	474.1 ± 276.5	863.0 ± 380.3	9058.9 ± 2140.2
Non-distal	33	667.5 ± 444.4	6278.5 ± 2368.0	494.6 ± 238.6	887.7 ± 341.7	9537.0 ± 2073.7
Classification
Intestinal	40	586.0 ± 381.1	5895.3 ±2315.7	472.3 ± 216.9	872.8 ± 361.7	8982.6 ± 2408.5
Diffuse or mixed	36	585.5 ± 436.4	6362.2 ± 2585.0	492.6 ± 367.2	874.6 ± 366.7	9522.0 ± 1795.4
T stage+
T1 + T2	12	635.6 ± 291.3	4843.4 ± 1682.9	465.3 ± 248.0	661.4 ± 383.3	8144.9 ± 1804.8
T3 + T4	46	484.1 ± 377.1	6378.0 ± 2345.8a	501.9 ± 286.4	872.3 ± 364.6	9344.9 ± 2254.5
Lymph node+
Negative	8	597.4 ± 476.5	5450.7 ± 2381.5	397.3 ± 116.9	717.5 ± 364.9	8843.8 ± 2419.8
Positive	50	503.2 ± 346.2	6065.6 ± 2367.4	514.1 ± 291.8	828.8 ± 377.8	9065.2 ± 2076.8
Metastasis
Absent	42	517.0 ± 331.5	5918.8 ± 2456.4	493.4 ± 283.9	779.1 ± 396.5	9007.8 ± 2297.8
Present	34	670.5 ±478.8	6415.5 ± 2464.3	470.1 ± 228.8	990.7 ± 277.1a	9586.1 ± 1838.1
Stage
1 + 2	13	586.5 ± 400.1	4848.8 ± 1948.7	458.6 ± 225.1	633.1 ± 365.1	8785.6 ± 2082.9
3 + 4	63	585.5 ± 413.3	6407.7 ± 2477.9a	488.1 ± 267.1	923.4 ± 343.4b	9365.8 ± 2119.7
Differentiation
Well	6	335.9 ± 310.5	4386.9 ± 2653.1	363.3 ± 102.0	595.5 ± 341.1	7265.1 ± 2188.0
Moderate + poor	70	607.1 ± 410.4	6291.4 ± 2399.2	493.3 ± 266.4	897.6 ± 355.8a	9438.1 ± 2029.6a

^aP < 0.05 and

^bP < 0.01 vs determined in patients who had surgical resections (n = 58).